The recommendation builds on the committee’s June 2024 vote for the use of RSV vaccines for people aged 60 to 74 at high risk ...

The ACIP has now recommended the use of GSK’s RSV vaccine, Arexvy, and PFE’s RSV vaccine, Abrysvo, in adults aged 50-59 who are at high risk of severe RSV disease. Individuals with underlying ...

GlaxoSmithKline (GSK) and Pfizer filed a stipulation to dismiss with prejudice GSK’s litigation in the United States District ...

In addition to increasing vaccine coverage in older adults, they need to monitor the changing epidemiology of pneumococcal serotypes ... funding from Wyeth/Pfizer, GSK, is a member of advisory ...

1 Tony Wood, Chief Scientific Officer at GSK, said: "We welcome this positive recommendation that can help strengthen disease prevention efforts in the US. Pentavalent vaccines can reduce the ...

GSK (GSK) announced that the US CDC’s Advisory Committee on Immunization Practices has voted to recommend use of Penmvevy as part of the ...

Within the current pneumococcal vaccine market, Pfizer, Merck (MRK) and GSK (GSK) have comprised the significant majority of market share and sales, with Pfizer’s PCV13 and PCV20, Merck’s ...

GSK (GSK.L), opens new tab said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its best-selling shingles vaccine lowers the risk of dementia.

GSK (GSK) said it is “pleased” that the Advisory Committee on Immunization Practices voted in favor of recommending the use of RSV vaccines ...

As one of the largest pharmaceutical and vaccine companies, GSK has used its vast resources to create the next generation of healthcare treatments. The company's innovative new product lineup and ...